Compare Citius Pharmaceuticals Inc (CTXR) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Tencent Music Entertainment Group - ADR — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Tencent Music Entertainment Group - ADR trades at $8.38 (market cap $12.83B). The key difference: Tencent Music Entertainment Group - ADR is far larger — about 942× Citius Pharmaceuticals Inc's market cap, and Tencent Music Entertainment Group - ADR pays a 3.02% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Tencent Music Entertainment Group - ADR for 67 Days on average.
| CTXR | TME | |
|---|---|---|
Market Cap | $13.62M | $12.83B |
Volume | 132,438 | 3,618,478 |
Sector | Health | Media |
52-Week High | $1.82 | $23.71 |
52-Week Low | $0.48 | $7.74 |
Typical Hold Time | 17 Days | 67 Days |
Enterprise Value | $3.79M | $10.77B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
Tencent Music Entertainment (TME) trades at $7.96, down 0.38% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust revenue growth to $32.9B in 2025 and net income of $11.06B, with improving profit margins. Recent developments include a $1B notes offering and a $400M share repurchase program, reflecting financial discipline. Analyst consensus is mixed with 41.7% buy ratings but a $12.50 price target suggesting significant upside from current levels.
TME presents a compelling value opportunity with attractive valuation multiples (P/E 9.33, P/S 2.46) and strong profitability metrics. However, investors face risks from intense competition, regulatory oversight in China, and recent earnings misses. The stock's current discount to analyst targets offers potential upside, but requires monitoring of user growth trends and competitive pressures from short-form video platforms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
